Kala Bio Inc (KALA) Stock Price, Quote & News

Company Profile

KALA BIO, Inc., a biopharmaceutical company, engages in the development of an on-premises artificial intelligence (AI) infrastructure platform for biotechnology research applications in the United States. The company develops Researgency, an agentic AI research platform for private enterprise AI deployment. Its platform intends to utilize the KPI-012 clinical development dataset as a proof-of-concept validation environment, as well as the mesenchymal stem cell secretome (MSC-S) and persistent co...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 996 5252

Website: www.kalarx.com

Address:

1167 Massachusetts Avenue, Arlington, United States

Ferguson5 Aug. 10 at 6:56 PM

$KALA filed for a $250M at-the-market offering in July 2026. That's potentially a significant source of capital for acquisitions/development, although it also creates substantial dilution risk...,

0 · Reply

dario2580 Aug. 7 at 11:00 PM

$KALA Reported EPS was -$0.14 vs. roughly $0.20 expected, a meaningful beat..

0 · Reply

dario2580 Aug. 7 at 10:58 PM

$KALA Around $13–14M, so relatively small positive catalysts can produce very large percentage moves...

0 · Reply

Roronao Aug. 5 at 12:30 PM

$QLYS $KALA Z

0 · Reply

Roronao Jul. 30 at 10:54 PM

$NOW $KALA ><watchlist~>

0 · Reply

Fakhrul123 Jul. 30 at 8:21 AM

$KALA is there anyone buying this shit to bring down the average?

0 · Reply

ony2k Jul. 25 at 5:19 AM

$KALA Im still waiting for this pos to do what NBY did.

0 · Reply

nonamestockz Jul. 24 at 5:32 PM

$KALA waiting for .30s

0 · Reply

MrAlientrader Jul. 24 at 2:39 PM

$KALA join me short this to sub $0.1 again

1 · Reply

Lyn30 Jul. 23 at 10:12 PM

$KALA Watching this one for entry again. Will buy when all scared to buy

0 · Reply

KALA BIO Registration statement: Registration filing

May 15, 2026, 7:00 AM EDT - 3 months ago

KALA BIO Quarterly report: Q1 2026

2026-05-12T17:59:22.000Z - 3 months ago

Kala Bio falls -21.7%

2026-05-07T22:27:13.000Z - 3 months ago

Kala Bio files $350M mixed securities shelf

2026-05-07T18:28:35.000Z - 3 months ago

Kala Bio announces reverse stock split

May 7, 2026, 9:00 AM EDT - 3 months ago

KALA BIO Announces Reverse Stock Split

May 7, 2026, 8:00 AM EDT - 3 months ago

KALA BIO Registration statement: Registration filing

2026-04-21T12:34:59.000Z - 3 months ago

Kala Bio ‘celebrates’ U.S. Executive Order for psychedelic medicine

Apr 21, 2026, 7:00 AM EDT - 3 months ago

Kala Bio Celebrates Trump Executive Order as Game-Changer for Psychedelic Medicine

Apr 15, 2026, 7:00 AM EDT - 4 months ago

KALA BIO Annual report: Q4 2025

Apr 1, 2026, 6:45 AM EDT - 4 months ago

Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities

Mar 30, 2026, 8:45 AM EDT - 4 months ago

KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live

2026-03-18T13:05:59.000Z - 5 months ago

Red Light Holland engages Kala Bio with its Researgency.ai platform

Mar 18, 2026, 9:00 AM EDT - 5 months ago

Red Light Holland Engages Kala Bio's Researgency.AI Platform to Support Clinical Development of Filament's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 18, 2026, 8:15 AM EDT - 5 months ago

Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate

Mar 11, 2026, 11:18 AM EDT - 5 months ago

Younet.ai Highlights Researgency.ai Collaboration with Kala Bio (KALA) as New "AutoResearch" Milestone Signals the Rise of Autonomous Research Agents

2026-03-11T12:00:18.000Z - 5 months ago

KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’

PLTR

2026-03-11T10:40:33.000Z - 5 months ago

Kala Bio poised to ship first commercial AI product in about 14 days

Mar 11, 2026, 6:30 AM EDT - 5 months ago

Kala Bio Launches a Revolution for Biotech- First AI Agent Deploying in 14 Days as $180 Billion Agentic AI Healthcare Revolution Accelerates

2026-03-04T11:45:29.000Z - 5 months ago

Kala Bio announces initiative to build AI infrastructure platform

Mar 4, 2026, 6:30 AM EST - 5 months ago

KALA BIO Announces Strategic Initiative to Deploy and Continue to Develop an On-Premises AI Infrastructure Platform for the Biotech Industry; Enters Into Platform Development and Exclusive License Agreement for Proprietary AI Research Platform “Researgency”

Feb 10, 2026, 7:00 AM EST - 6 months ago

KALA BIO Registration statement: Registration Filing

2026-02-10T11:15:48.000Z - 6 months ago

Kala Bio files to sell 241.44M shares of common stock for holders

Jan 30, 2026, 11:00 AM EST - 6 months ago

KALA BIO Transcript: AGM 2026

Jan 26, 2026, 7:00 AM EST - 7 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 6, 2026, 7:00 AM EST - 7 months ago

KALA BIO Proxy statement: Proxy Filing

Jan 5, 2026, 4:10 PM EST - 7 months ago

KALA BIO Settles Approximately $10.6 million of Debt

Dec 30, 2025, 7:00 AM EST - 7 months ago

KALA BIO Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 8 months ago

KALA BIO Proxy statement: Proxy Filing

2025-12-04T15:55:28.000Z - 8 months ago

Kala Bio announces $10M registered direct offering priced at-the-market

Dec 4, 2025, 10:45 AM EST - 8 months ago

KALA BIO Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

2025-12-01T12:11:04.000Z - 9 months ago

Kala Bio enters securities purchase agreement with David Lazar, names him CEO

Nov 19, 2025, 4:00 PM EST - 9 months ago

KALA BIO Quarterly report: Q3 2025

2025-09-30T13:35:26.000Z - 11 months ago

Kala Bio downgraded to Neutral from Outperform at Mizuho

2025-09-29T17:25:13.000Z - 11 months ago

Kala Bio downgraded to Neutral from Buy at H.C. Wainwright

2025-09-29T17:25:08.000Z - 11 months ago

H.C. Wainwright downgrades Kala Bio to Neutral after CHASE trial miss

2025-09-29T15:20:15.000Z - 11 months ago

Kala Bio shared no details on study miss, says Mizuho

2025-09-29T15:15:13.000Z - 11 months ago

Kala Pharmaceuticals downgraded to Market Perform at LifeSci Capital

2025-09-29T13:40:36.000Z - 11 months ago

Kala Pharmaceuticals trading resumes

Sep 10, 2025, 2:00 PM EDT - 11 months ago

KALA BIO Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 1:00 PM EDT - 1 year ago

KALA BIO Transcript: H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q2 2025

Aug 8, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Transcript: Status Update

Jul 16, 2025, 4:00 PM EDT - 1 year ago

KALA BIO Slides: Status Update

Jul 9, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Announces Completion of Enrollment in CHASE Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Jun 5, 2025, 1:25 PM EDT - 1 year ago

KALA BIO Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

KALA BIO to Present at Jefferies Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Quarterly report: Q1 2025

May 14, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q1 2025

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Annual report: Q4 2024

Mar 31, 2025, 8:00 AM EDT - 1 year ago

KALA BIO Earnings release: Q4 2024

Mar 5, 2025, 11:50 AM EST - 1 year ago

KALA BIO Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 12, 2025, 8:00 AM EST - 1 year ago

KALA BIO Announces Chief Executive Officer Transition

Jan 24, 2025, 7:00 AM EST - 1 year ago

KALA BIO Registration statement: Registration Filing

Dec 30, 2024, 8:00 AM EST - 1 year ago

KALA BIO Announces $10,750,000 Private Placement

Dec 4, 2024, 11:30 AM EST - 1 year ago

KALA BIO Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Quarterly report: Q3 2024

Nov 12, 2024, 7:00 AM EST - 1 year ago

KALA BIO Earnings release: Q3 2024

Aug 15, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Transcript: H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Quarterly report: Q2 2024

Aug 6, 2024, 7:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q2 2024

Jul 25, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Registration statement: Registration Filing

Jun 5, 2024, 12:30 PM EDT - 2 years ago

KALA BIO Transcript: Jefferies 2024 Global Healthcare Conference

May 30, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

May 14, 2024, 4:05 PM EDT - 2 years ago

KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

KALA BIO Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Earnings release: Q4 2023

Mar 29, 2024, 8:00 AM EDT - 2 years ago

KALA BIO Annual report: Q4 2023

Mar 4, 2024, 12:50 PM EST - 2 years ago

KALA BIO Transcript: TD Cowen 44th Annual Health Care Conference 2024

Feb 26, 2024, 8:00 AM EST - 2 years ago

KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference

Feb 13, 2024, 12:00 PM EST - 2 years ago

KALA BIO Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Jan 19, 2024, 4:01 PM EST - 2 years ago

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2023, 8:00 AM EST - 2 years ago

KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Quarterly report: Q3 2023

Nov 13, 2023, 7:00 AM EST - 2 years ago

KALA BIO Earnings release: Q3 2023

Sep 5, 2023, 8:00 AM EDT - 3 years ago

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 4, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q2 2023

Aug 4, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q2 2023

Aug 2, 2023, 4:01 PM EDT - 3 years ago

KALA BIO to Participate in Upcoming Investor Conferences in August

Jul 19, 2023, 4:01 PM EDT - 3 years ago

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 11, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

May 9, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 9, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Registration statement: Registration Filing

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Quarterly report: Q1 2023

May 9, 2023, 7:00 AM EDT - 3 years ago

KALA BIO Earnings release: Q1 2023

Apr 28, 2023, 8:00 AM EDT - 3 years ago

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED

Mar 27, 2023, 8:00 AM EDT - 3 years ago

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED

Mar 13, 2023, 8:00 AM EDT - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Mar 8, 2023, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Mar 3, 2023, 8:00 AM EST - 3 years ago

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Annual report: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Earnings release: Q4 2022

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 3, 2023, 7:00 AM EST - 3 years ago

KALA BIO Registration statement: Registration Filing

Mar 1, 2023, 7:00 AM EST - 3 years ago

KALA BIO Proxy statement: Proxy Filing

Dec 30, 2022, 12:02 PM EST - 3 years ago

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment

Dec 28, 2022, 6:48 AM EST - 3 years ago

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment

Dec 27, 2022, 4:01 PM EST - 3 years ago

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Nov 28, 2022, 4:02 PM EST - 4 years ago

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

Nov 28, 2022, 4:01 PM EST - 4 years ago

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

Nov 8, 2022, 8:30 AM EST - 4 years ago

KALA BIO Quarterly report: Q3 2022

Nov 8, 2022, 8:30 AM EST - 4 years ago

KALA BIO Earnings release: Q3 2022

Nov 8, 2022, 8:00 AM EST - 4 years ago

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 1, 2022, 7:30 AM EDT - 4 years ago

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

Oct 20, 2022, 7:30 AM EDT - 4 years ago

Kala Pharmaceuticals Announces Reverse Stock Split

Sep 9, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Sep 6, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

Aug 19, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Aug 18, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Quarterly report: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Earnings release: Q2 2022

Aug 11, 2022, 11:15 AM EDT - 4 years ago

KALA BIO Slides: Q2 2022

Aug 11, 2022, 7:00 AM EDT - 4 years ago

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 4, 2022, 4:01 PM EDT - 4 years ago

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in August

Jul 11, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc

Jun 2, 2022, 8:00 AM EDT - 4 years ago

Kala Pharmaceuticals to Present at Jefferies Healthcare Conference

May 31, 2022, 8:00 AM EDT - 4 years ago

KALA BIO Proxy statement: Proxy Filing

May 23, 2022, 12:01 AM EDT - 4 years ago

Kala Announces Entry into Definitive Agreement to Sell EYSUVIS® and INVELTYS® to Alcon Inc.

May 16, 2022, 9:33 AM EDT - 4 years ago

KALA BIO Earnings Call Transcript: Q1 2022

May 16, 2022, 9:33 AM EDT - 4 years ago

KALA BIO Quarterly report: Q1 2022

May 16, 2022, 7:00 AM EDT - 4 years ago

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

Ferguson5 Aug. 10 at 6:56 PM

$KALA filed for a $250M at-the-market offering in July 2026. That's potentially a significant source of capital for acquisitions/development, although it also creates substantial dilution risk...,

0 · Reply

dario2580 Aug. 7 at 11:00 PM

$KALA Reported EPS was -$0.14 vs. roughly $0.20 expected, a meaningful beat..

0 · Reply

dario2580 Aug. 7 at 10:58 PM

$KALA Around $13–14M, so relatively small positive catalysts can produce very large percentage moves...

0 · Reply

Roronao Aug. 5 at 12:30 PM

$QLYS $KALA Z

0 · Reply

Roronao Jul. 30 at 10:54 PM

$NOW $KALA ><watchlist~>

0 · Reply

Fakhrul123 Jul. 30 at 8:21 AM

$KALA is there anyone buying this shit to bring down the average?

0 · Reply

ony2k Jul. 25 at 5:19 AM

$KALA Im still waiting for this pos to do what NBY did.

0 · Reply

nonamestockz Jul. 24 at 5:32 PM

$KALA waiting for .30s

0 · Reply

MrAlientrader Jul. 24 at 2:39 PM

$KALA join me short this to sub $0.1 again

1 · Reply

Lyn30 Jul. 23 at 10:12 PM

$KALA Watching this one for entry again. Will buy when all scared to buy

0 · Reply

MrAlientrader Jul. 22 at 8:13 PM

$KALA the market believe this company has no value

1 · Reply

jv39 Jul. 22 at 1:43 PM

$KALA A new all time low. So what else is new🖕🖕🖕

0 · Reply

Bigdubs Jul. 21 at 8:21 PM

$KALA insiders got their shares at .5, safe to say that’s gonna be a line where I might buy in. At this point we are hoping for a QUCY moment (another David L. Shells).

2 · Reply

Alexandergomis Jul. 20 at 5:48 PM

$KALA They recently had a reverse split. Is it possible for them to do another one in August?? 🤯

1 · Reply

Beginer_Trading Jul. 19 at 1:34 PM

$KALA 10 cents by end of aug

0 · Reply

MrAlientrader Jul. 17 at 7:12 PM

$KALA just follow the shorts, the only way to get your money back. There is no support, it’s a dead company

0 · Reply

jv39 Jul. 17 at 7:04 PM

$KALA Fuck the assholes that are behind this. They deserve a slow death

0 · Reply

MrE___ Jul. 17 at 3:22 PM

$KALA Watching. When the customer complaints reach an all time high around here, I will big boi buy.

0 · Reply

Banelamhh Jul. 16 at 11:07 PM

$KALA This is a scam. Whoever is running this company should be in jail by now. I pray to God that the money I lost here will be returned somehow. If not, I hope those responsible face the consequences for what they’ve done. I will never forgive the loss I suffered because of this.

0 · Reply

MrAlientrader Jul. 16 at 9:16 PM

$KALA this is another dilution scam like $ADTX with fake useless products, the only purpose is to feed the management

0 · Reply

LongLife1 Jul. 16 at 7:34 PM

$KALA Lazar is busy on to restructuring next - leach

0 · Reply

newtimestrades Jul. 16 at 7:01 PM

$KALA going to 0.03 before delist

0 · Reply

Market Cap	14.46M
Revenue (ttm)	0.00
Net Income (ttm)	-26.98M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	88,054
Avg Vol	150,196
Day's Range	N/A - N/A
Shares Out	19.34M
Stochastic %K	50%
Beta	-2.26
Analysts	Strong Buy
Price Target	$1.50